Evolution of drug metabolism: Hitchhiking the technology bandwagon

Clinical and Experimental Pharmacology and Physiology

Volumn 29, Issue 11, 2002, Pages 1040-1044

  Miners, John O ^a  

^a FLINDERS MEDICAL CENTRE   (Australia)

Author keywords

Cytochrome P450; Drug metabolism; Human; Interindividual variability; Uridine diphosphate glucuronosyltransferase

Indexed keywords

CLOZAPINE; COUMARIN; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; DIAZEPAM; DIETHYLDITHIOCARBAMIC ACID; ERYTHROMYCIN; FLUCONAZOLE; FURAFYLLINE; GLUCURONOSYLTRANSFERASE; KETOCONAZOLE; LOSARTAN; MEPHENYTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; QUINIDINE; SULFAPHENAZOLE; TACRINE; THEOPHYLLINE; TOLBUTAMIDE; TROLEANDOMYCIN; UNINDEXED DRUG; WARFARIN;

COMPUTER MODEL; CONFERENCE PAPER; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVITY; EVOLUTION; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENETIC POLYMORPHISM; GENOMICS; HUMAN; PREDICTION; PROTEOMICS; SEQUENCE HOMOLOGY; TECHNOLOGY; X RAY CRYSTALLOGRAPHY;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; LIVER; PHARMACEUTICAL PREPARATIONS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0036400373     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.2002.03768.x     Document Type: Conference Paper

References (34)

1. Meffin PJ, Miners JO. The high performance liquid chromatographic measurement of drugs in biological fluids. In: Bridges JW, Chasseaud LF (eds). Progress in Drug Metabolism. John Wiley & Sons, Chichester. 1980; Ch. 5.
2. Birkett DJ, Miners JO, Attwood JA. Evidence for a dual action of sulfinpyrazone on drug metabolism in man: Theophylline-sulfinpyrazone interaction. Br. J. Clin. Pharmacol. 1983; 15: 567-9.
3. Grygiel JJ, Miners JO, Drew R, Birkett DJ. Differential effects of cimetidine on theophylline metabolic pathways. Eur. J. Clin. Pharmacol. 1984; 26: 335-40.
4. Miners JO, Wing LMH, Lillywhite KJ, Robson RA. Selectivity and dose-dependency of the inhibitory effect of propranolol on theophylline metabolism in man. Br. J. Clin. Pharmacol. 1985; 20: 219-23.
5. Miners JO, Foenander T, Wanwimolruk S, Gallus SA, Birkett DJ. The effect of sulfinpyrazone on oxidative drug metabolism in man: Inhibition of tolbutamide elimination. Eur. J. Clin. Pharmacol. 1982; 22: 321-6.
6. Miners JO, Wing LMH, Lillywhite KJ, Robson RA. Failure of therapeutic doses of β-adrenoceptor antagonists to alter the disposition of tolbutamide in man. Br. J. Clin. Pharmacol. 1984; 18: 853-60.
7. Veronese ME, Miners JO, Randles D, Gregov D, Birkett DJ. Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolisers. Clin. Pharmacol. Ther. 1990; 47: 403-11.
8. Miners JO, Wing LMH, Birkett DJ. Normal metabolism of debrisoquine and theophylline in a poor metaboliser of tolbutamide. Aust. N.Z. J. Med. 1985; 15: 348-9.
9. Miners JO, Attwood J, Birkett DJ. Influence of sex and oral contraceptive steroids on paracetamol metabolism. Br. J. Clin. Pharmacol. 1983; 16: 503-9.
10. Miners JO, Attwood J, Birkett DJ. Determinants of acetaminophen metabolism. Effect of inhibitors and inducers of drug metabolism on acetaminophen's metabolic pathways. Clin. Pharmacol. Ther. 1984; 35: 480-6.
11. Miners JO, Robson RA, Birkett DJ. Paracetamol metabolism in pregnancy. Br. J. Clin. Pharmacol. 1986; 22: 359-62.
12. Robson RA, Miners JO, Matthews AP et al. Characterisation of theophylline metabolism by human liver microsomes. Inhibition and immunochemical studies. Biochem. Pharmacol. 1988; 37: 1651-9.
13. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME, Birkett DJ. Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P450 dependent xenobiotic oxidations. Biochem. Pharmacol. 1988; 37: 1137-44.
14. Lelo A, Miners JO, Robson RA, Birkett DJ. Quantitative assessment of caffeine partial clearances in man. Br. J. Clin. Pharmacol. 1986; 22: 183-6.
15. Tassaneeyakul W, Mohamed Z, Birkett DJ et al. Caffeine as a probe for human cytochromes P450: Validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibition techniques. Pharmacogenetics 1992; 2: 173-83.
16. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Miners JO. Direct characterization of the selectivity of furafylline as an inhibitor of human cytochromes P450 1A1 and 1A2. Pharmacogenetics 1994; 4: 281-4.
17. Tassaneeyakul W, Veronese ME, Birkett DJ, Gonzalez FJ, Miners JO. Validation of 4-nitrophenol as anin vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochem. Pharmacol. 1993; 46: 1975-81.
18. Miners JO, Birkett DJ. Use of tolbutamide as a substrate probe for human hepatic cytochrome P450. Methods Enzymol. 1996; 272: 139-45.
19. Miners JO, Coulter S, Birkett DJ, Goldstein JA. Torsemide metabolism by CYP2C9 variants and other CYP2C family enzymes. Pharmacogenetics 2000; 10: 267-70.
20. Andersson T, Miners JO, Veronese ME et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br. J. Clin. Pharmacol. 1993; 36: 521-30.
21. Tassaneeyakul W, Birkett DJ, McManus ME et al. Caffeine metabolism by human hepatic cytochromes P450: Contributions of 1A2, 2E1, and 3A isoforms.Biochem. Pharmacol. 1994; 47: 1767-76.
22. Miners JO, Veronese ME, Birkett DJ. In vitro approaches for the prediction of human drug metabolism. Annu. Rep. Med. Chem. 1994; 29: 307-16.
23. Miners JO, Rees DLP, Valente L, Veronese ME, Birkett DJ. Human hepatic cytochrome P4502C9 catalyzes the rate-limiting pathway of torsemide metabolism. J. Pharmacol. Exp. Ther. 1995; 272: 1076-81.
24. Tassaneeyakul W, Birkett DJ, Edwards JW et al. Human cytochrome P450 isoform specificity in the regioselective metabolism of toluene ando-,m- andp-xylene.J. Pharmacol. Exp. Ther. 1996; 276: 101-8.
25. Boase S, Miners JO. In vitro-in vivo correlations for drugs eliminated by glucuronidation: Investigations with the model substrate zidovudine. Br. J. Clin. Pharmacol. 2002 (in press).
26. Veronese ME, Doecke CJ, Mackenzie PI et al. Site-directed mutation studies of human liver cytochrome P450 isoenzymes in the CYP2C subfamily. Biochem. J. 1993; 289: 533-8.
27. Sullivan-Klose TH, Ghanayem BI, Bell DA et al. Role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6: 341-9.
28. Miners JO. CYP2C9 polymorphism. Impact on tolbutamide pharmacokinetics and response. Pharmacogenetics 2002; 12: 91-2.
29. Bhasker CR, Miners JO, Coulter S, Birkett DJ. Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 1997; 7: 51-8.
30. Williams PA, Cosme J, Sridhar V, Johnson EF, McRae DE. Mammalian microsomal cytochrome P450 monooxygenase: Structural adaptations for membrane binding and functional diversity. Mol. Cell 2000; 5: 121-31.
31. Bhasker CR, McKinnon W, Stone A et al. Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: Ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 2000; 10: 679-85.
32. Miners JO, McKinnon RA, Mackenzie PI. Genetic polymorphism of UDP-glucuronosyltransferases and their functional significance. Toxicology 2002 (in press).
33. Miners JO, Valente L, Lillywhite KJ et al. Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug. Cancer Res. 1997; 57: 284-9.
34. Sorich MJ, Smith PA, McKinnon RA, Miners JO. Pharmacophore and quantitative structure activity relationship modelling of UDP-glucuronosyltransferase 1A1 (UGT1A1) substrates. Pharmacogenetics 2002 (in press).